{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:28:09Z","timestamp":1769599689953,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00392-021-01859-2","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T11:05:12Z","timestamp":1619780712000},"page":"1612-1624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-8463","authenticated-orcid":false,"given":"Xavier","family":"Rossello","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Francisca","family":"Caimari","sequence":"additional","affiliation":[]},{"given":"Zohra","family":"Lamiral","sequence":"additional","affiliation":[]},{"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[]},{"given":"Cyrus","family":"Mehta","sequence":"additional","affiliation":[]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"1859_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12170-015-0462-5","volume":"9","author":"SAE Peters","year":"2015","unstructured":"Peters SAE, Huxley RR, Sattar N, Woodward M (2015) Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. Curr Cardiovasc Risk Rep 9:1\u20137. https:\/\/doi.org\/10.1007\/s12170-015-0462-5","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"1859_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/2048872618803701","volume":"8","author":"X Rossello","year":"2019","unstructured":"Rossello X, Ferreira JP, McMurray JJ et al (2019) Editor\u2019s choice-impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. Eur Hear J Acute Cardiovasc Care 8:231\u2013241. https:\/\/doi.org\/10.1177\/2048872618803701","journal-title":"Eur Hear J Acute Cardiovasc Care"},{"key":"1859_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"key":"1859_CR4","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jamacardio.2020.0359","volume":"5","author":"AS Tahhan","year":"2020","unstructured":"Tahhan AS, Vaduganathan M, Greene SJ et al (2020) Enrollment of older patients, women, and racial\/ethnic minority groups in contemporary acute coronary syndrome clinical trials: a systematic review. JAMA Cardiol 5:714\u2013722. https:\/\/doi.org\/10.1001\/jamacardio.2020.0359","journal-title":"JAMA Cardiol"},{"key":"1859_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"key":"1859_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"key":"1859_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the carmelina randomized clinical trial. JAMA 321:69\u201379. https:\/\/doi.org\/10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"1859_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322:1155\u20131166. https:\/\/doi.org\/10.1001\/jama.2019.13772","journal-title":"JAMA"},{"key":"1859_CR9","unstructured":"Go Red for Women-American heart association. In: https:\/\/www.goredforwomen.org\/en\/about-go-red-for-women. https:\/\/www.goredforwomen.org\/en\/about-go-red-for-women. Accessed 27 Aug 2020"},{"key":"1859_CR10","unstructured":"Women\u2019s heart alliance. https:\/\/www.womensheartalliance.org\/about\/. Accessed 27 Aug 2020"},{"key":"1859_CR11","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1093\/eurheartj\/ehaa277","volume":"41","author":"TF L\u00fcscher","year":"2020","unstructured":"L\u00fcscher TF, Miller VM, Bairey Merz CN, Crea F (2020) Diversity is richness: why data reporting according to sex, age, and ethnicity matters. Eur Heart J 41:3117\u20133121. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa277","journal-title":"Eur Heart J"},{"key":"1859_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1161\/CIR.0b013e31820faaf8","volume":"123","author":"L Mosca","year":"2011","unstructured":"Mosca L, Benjamin EJ, Berra K et al (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women\u20142011 update: a guideline from the American heart association. Circulation 123:1243\u20131262. https:\/\/doi.org\/10.1161\/CIR.0b013e31820faaf8","journal-title":"Circulation"},{"key":"1859_CR13","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021\u20133104","journal-title":"Eur Heart J"},{"key":"1859_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijcard.2016.11.246","volume":"228","author":"X Rossello","year":"2017","unstructured":"Rossello X, Yellon DM (2017) A new era in the management of type 2 diabetes: is cardioprotection at long last a reality? Int J Cardiol 228:198\u2013200. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.246","journal-title":"Int J Cardiol"},{"key":"1859_CR15","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528\u20132536. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040130","journal-title":"Circulation"},{"key":"1859_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327\u20131335. https:\/\/doi.org\/10.1056\/NEJMoa1305889","journal-title":"N Engl J Med"},{"key":"1859_CR17","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:2067\u20132076. https:\/\/doi.org\/10.1016\/S0140-6736(14)62225-X","journal-title":"Lancet"},{"key":"1859_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","volume":"162","author":"WB White","year":"2011","unstructured":"White WB, Bakris GL, Bergenstal RM et al (2011) Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 162:620\u2013626. https:\/\/doi.org\/10.1016\/j.ahj.2011.08.004","journal-title":"Am Heart J"},{"key":"1859_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/dom.13136","volume":"20","author":"Y-C Hwang","year":"2018","unstructured":"Hwang Y-C, Morrow DA, Cannon CP et al (2018) High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (examination of cardiovascular outcomes with alogliptin versus standard of care) trial. Diabetes Obes Metab 20:654\u2013659. https:\/\/doi.org\/10.1111\/dom.13136","journal-title":"Diabetes Obes Metab"},{"key":"1859_CR20","doi-asserted-by":"publisher","first-page":"e009114","DOI":"10.1161\/JAHA.118.009114","volume":"7","author":"WB White","year":"2018","unstructured":"White WB, Jalil F, Cushman WC et al (2018) Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMINE trial. J Am Heart Assoc 7:e009114. https:\/\/doi.org\/10.1161\/JAHA.118.009114","journal-title":"J Am Heart Assoc"},{"key":"1859_CR21","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","volume":"135","author":"MA Cavender","year":"2017","unstructured":"Cavender MA, White WB, Jarolim P et al (2017) Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (examination of cardiovascular outcomes with alogliptin versus standard of care). Circulation 135:1911\u20131921. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024632","journal-title":"Circulation"},{"key":"1859_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2337\/dc16-0303","volume":"39","author":"WB White","year":"2016","unstructured":"White WB, Kupfer S, Zannad F et al (2016) Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Diabetes Care 39:1267\u20131273. https:\/\/doi.org\/10.2337\/dc16-0303","journal-title":"Diabetes Care"},{"key":"1859_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ejhf.1740","volume":"22","author":"X Rossello","year":"2020","unstructured":"Rossello X, Ferreira JP, Pocock SJ et al (2020) Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. Eur J Heart Fail 22:834\u2013844. https:\/\/doi.org\/10.1002\/ejhf.1740","journal-title":"Eur J Heart Fail"},{"key":"1859_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00392-018-1378-0","volume":"108","author":"X Rossello","year":"2019","unstructured":"Rossello X, Ariti C, Pocock SJ et al (2019) Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clin Res Cardiol 108:477\u2013486. https:\/\/doi.org\/10.1007\/s00392-018-1378-0","journal-title":"Clin Res Cardiol"},{"key":"1859_CR25","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"key":"1859_CR26","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/diacare.28.12.2864","volume":"28","author":"AF Brown","year":"2005","unstructured":"Brown AF, Gregg EW, Stevens MR et al (2005) Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the translating research into action for diabetes (TRIAD) study. Diabetes Care 28:2864\u20132870. https:\/\/doi.org\/10.2337\/diacare.28.12.2864","journal-title":"Diabetes Care"},{"key":"1859_CR27","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials. Circulation 139:2022\u20132031. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation"},{"key":"1859_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.whi.2005.04.003","volume":"16","author":"R Correa-de-Araujo","year":"2006","unstructured":"Correa-de-Araujo R, Stevens B, Moy E et al (2006) Gender differences across racial and ethnic groups in the quality of care for acute myocardial infarction and heart failure associated with comorbidities. Women\u2019s Health Issues 16:44\u201355. https:\/\/doi.org\/10.1016\/j.whi.2005.04.003","journal-title":"Women\u2019s Health Issues"},{"key":"1859_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.whi.2005.08.003","volume":"16","author":"R Correa-de-Araujo","year":"2006","unstructured":"Correa-de-Araujo R, McDermott K, Moy E (2006) Gender differences across racial and ethnic groups in the quality of care for diabetes. Women\u2019s Health Issues 16:56\u201365. https:\/\/doi.org\/10.1016\/j.whi.2005.08.003","journal-title":"Women\u2019s Health Issues"},{"key":"1859_CR30","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/s0140-6736(19)31792-1","volume":"394","author":"BT Santema","year":"2019","unstructured":"Santema BT, Ouwerkerk W, Tromp J et al (2019) Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 394:1254\u20131263. https:\/\/doi.org\/10.1016\/s0140-6736(19)31792-1","journal-title":"Lancet"},{"key":"1859_CR31","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jchf.2019.08.017","volume":"7","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Rossello X, Eschalier R et al (2019) MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPAHSIS-HF, and TOPCAT. JACC Heart Fail 7:1012\u20131021. https:\/\/doi.org\/10.1016\/j.jchf.2019.08.017","journal-title":"JACC Heart Fail"},{"key":"1859_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ejhf.326","volume":"17","author":"JP Ferreira","year":"2015","unstructured":"Ferreira JP, Girerd N, Rossignol P, Zannad F (2015) Geographic differences in heart failure trials. Eur J Heart Fail 17:893\u2013905. https:\/\/doi.org\/10.1002\/ejhf.326","journal-title":"Eur J Heart Fail"},{"key":"1859_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijcard.2017.07.039","volume":"245","author":"X Rossell\u00f3","year":"2017","unstructured":"Rossell\u00f3 X, Huo Y, Pocock S et al (2017) Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. Int J Cardiol 245:27\u201334. https:\/\/doi.org\/10.1016\/j.ijcard.2017.07.039","journal-title":"Int J Cardiol"},{"key":"1859_CR34","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s00392-018-1254-y","volume":"107","author":"H Bueno","year":"2018","unstructured":"Bueno H, Rossello X, Pocock S et al (2018) Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome. Clin Res Cardiol 107:836\u2013844. https:\/\/doi.org\/10.1007\/s00392-018-1254-y","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01859-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T08:24:42Z","timestamp":1632990282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01859-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01859-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"XR, JPF, FC, ZL and CM have nothing to disclose. AS has received support from the FRSQ-Junior 1 clinician scientist award, the Alberta Innovates Health Solution Clinician Scientist fellowship, the European Society of Cardiology Young Investigator research grant, and has received support from Roche Diagnostics, Astrazeneca, Boeringer-Ingelheim, Novartis, Servier, Novo-Nordisk, and the Canadian Cardiovascular Society Bayer Vascular award. Dr Ferreira has received consulting fees from Boehringer-Ingelheim. GB reports other from Merck, Novo Nordisk, Vasular Dynamics, Bayer, Ionis, Alnylam, KBP Biosciences, outside the submitted work. CPC reports in calendar years 2018\u20132020: (1) Research Grants from: Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Novo Nordisk, Pfizer, and (2) Consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, Eli Lilly, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Rhoshan, Sanofi. WBW reports personal fees from Takeda Millenium Pharmaceuticals, outside the submitted work. FZ reports steering committee personal fees from Applied Therapeutics, Amgen, Bayer, Boehringer, Novartis, Janssen, Cellprothera and CVRx, advisory board personal fees from, AstraZeneca, Vifor Fresenius, Cardior, Cereno pharmaceutical, Corvidia, Merck, Myokardia, NovoNordisk and Owkin, stock options at Cereno and G3Pharmaceutical, and being the founder of the Global Cardiovascular Clinical Trialist Forum.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consents were obtained from each patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors agree with de publications of the present article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}